GHRH Analogs and Growth Hormone Secretagogues: Two Mechanisms Compared

Compounds grouped together as “growth hormone peptides” act through two different receptors. Treating them as interchangeable is the most common conceptual error in this category, and it matters for experimental design.

GHRH analogs

Growth hormone-releasing hormone is a hypothalamic peptide acting on the GHRH receptor, a class B1 GPCR on anterior pituitary somatotrophs. Activation raises cAMP and promotes both synthesis and release of growth hormone. Analogs in this class include sermorelin, CJC-1295 and tesamorelin.

Native GHRH is cleaved rapidly by DPP-4, so every practical analog addresses stability. Frohman and colleagues mapped the degradation directly, measuring cleavage sites and kinetics of GRH(1-29)-NH2 in human plasma in vitro and identifying DPP-4 N-terminal cleavage as the inactivating step (J Clin Invest, 1989; PMID 2565342).

Two stabilisation strategies appear in the literature:

• Albumin conjugation. Jetté and colleagues characterised CJC-1295 as a GRF(1-29) bioconjugate binding cysteine-34 of albumin, measuring GH secretion in cultured rat anterior pituitary cells and plasma GH in rats, along with resistance to DPP-IV cleavage (Endocrinology, 2005; PMID 15817669).
• N-terminal modification. Tesamorelin carries a trans-3-hexenoyl group on Tyr1. Ferdinandi and colleagues measured the resulting enzymatic stability, plasma elimination kinetics and IGF-1 response in rats, dogs and pigs (Basic Clin Pharmacol Toxicol, 2007; PMID 17214611).

Growth hormone secretagogues

Secretagogues act on a different receptor entirely: the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor. This is a class A GPCR signalling through Gq and phospholipase C rather than through cAMP. Ipamorelin is the archetype.

Raun and colleagues characterised ipamorelin as the first selective secretagogue, measuring GH release in primary rat pituitary cell culture and in anaesthetised rats and conscious swine, and showing GH release without the concomitant ACTH and cortisol elevation seen with earlier compounds in the class (Eur J Endocrinol, 1998; PMID 9849822). That selectivity is the defining property — earlier secretagogues activated the hypothalamic-pituitary-adrenal axis alongside the somatotropic one.

Downstream measurements in rodents include longitudinal bone growth (Johansen et al., Growth Horm IGF Res, 1999; PMID 10373343) and bone mineral content in adult female rats (Svensson et al., J Endocrinol, 2000; PMID 10828840).

Why the distinction matters experimentally

• Different receptors, different antagonists. A GHRH receptor antagonist will not block a secretagogue response, and vice versa. Choosing the wrong control invalidates the experiment.
• Different second messengers. cAMP/PKA for GHRH analogs, Gq/PLC and calcium mobilisation for GHS-R1a. If your readout is cAMP accumulation, a secretagogue may look inactive.
• Different desensitisation profiles. Because the receptors differ, so does behaviour under sustained exposure — relevant to any chronic-administration design.
• Combination effects. The two pathways converge on the same cell type, which is why blends pairing a GHRH analog with a secretagogue appear in the literature and why their combined effect is not simply additive.

Naming caution

Sermorelin appears in the primary literature as GRF(1-29)NH2 or GHRH(1-29)NH2 rather than under the trade name. If a literature search on the commercial name returns little, search the fragment notation — see our guide to peptide nomenclature.

Browse Growth Hormone Peptides.

All findings cited are from in vitro or animal models. All products referenced are supplied for laboratory research use only and are not approved for human consumption, clinical, or veterinary use.